- Home
- LPG vs CDTX Comparison
LPG vs CDTX Comparison
Compare LPG & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- CDTX
- Stock Information
- Founded
- LPG 2013
- CDTX 2012
- Country
- LPG United States
- CDTX United States
- Employees
- LPG N/A
- CDTX N/A
- Industry
- LPG Marine Transportation
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPG Consumer Discretionary
- CDTX Health Care
- Exchange
- LPG Nasdaq
- CDTX Nasdaq
- Market Cap
- LPG 1.3B
- CDTX 1.4B
- IPO Year
- LPG 2014
- CDTX 2015
- Fundamental
- Price
- LPG $30.07
- CDTX $65.22
- Analyst Decision
- LPG Strong Buy
- CDTX Strong Buy
- Analyst Count
- LPG 1
- CDTX 11
- Target Price
- LPG $35.00
- CDTX $57.00
- AVG Volume (30 Days)
- LPG 618.6K
- CDTX 479.3K
- Earning Date
- LPG 08-01-2025
- CDTX 08-07-2025
- Dividend Yield
- LPG 10.65%
- CDTX N/A
- EPS Growth
- LPG N/A
- CDTX N/A
- EPS
- LPG 1.15
- CDTX N/A
- Revenue
- LPG $320,692,009.00
- CDTX N/A
- Revenue This Year
- LPG $16.86
- CDTX N/A
- Revenue Next Year
- LPG N/A
- CDTX N/A
- P/E Ratio
- LPG $26.10
- CDTX N/A
- Revenue Growth
- LPG N/A
- CDTX N/A
- 52 Week Low
- LPG $16.66
- CDTX $10.14
- 52 Week High
- LPG $39.35
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- LPG 58.14
- CDTX 72.50
- Support Level
- LPG $29.65
- CDTX $60.30
- Resistance Level
- LPG $30.80
- CDTX $64.26
- Average True Range (ATR)
- LPG 0.95
- CDTX 3.19
- MACD
- LPG -0.11
- CDTX -0.72
- Stochastic Oscillator
- LPG 77.29
- CDTX 89.81
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.